Registration is open - make plans to attend
Get pricing and details
>
Conference 12033 > Paper 12033-63
Paper 12033-63

CT radiomics to predict early hepatic recurrence after resection for intrahepatic cholangiocarcinoma

In person: 24 February 2022 • 10:50 AM - 11:10 AM PST

Abstract

Intrahepatic cholangiocarcinoma (IHC) is an aggressive liver cancer. Although surgery is the only curative treatment most disease recurs within 2-years after resection. Early hepatic recurrence within a short period after surgery is common and eventually leads to death. Currently, there is no way to assess the risk of early recurrence. Methods to predict these risks would help physicians select the best treatment plan; patients at high risk could be treated early or at the time of surgery with chemotherapy or radiation. We propose a CT radiomics-based approach to predict early hepatic recurrence prior to surgery which obtained an AUC of 0.78 using an AdaBoost classifier.

Presenter

Memorial Sloan-Kettering Cancer Ctr. (United States)
Jayasree Chakraborty, assistant attending in the Department of Surgery (HPB service) Memorial Sloan Kettering Cancer Center, is an Electrical Engineer by training. She has been associated with machine learning and computer vision for more than 10 years. Her research area includes detection, diagnosis, prognosis, and treatment stratification for different cancers using medical imaging and machine learning. She has published more than 60 papers in reputed journals and conferences.
Presenter/Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States), Brigham and Women's Hospital (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Brigham and Women's Hospital (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Richard K. G. Do
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
T. Peter Kingham
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
Memorial Sloan-Kettering Cancer Ctr. (United States)
Author
William R. Jarnagin
Memorial Sloan-Kettering Cancer Ctr. (United States)